Abstract
Some data suggest that brothers of prostate cancer patients have higher disease risk than their fathers, supporting an X-linked or recessive mode of inheritance. However, higher observed frequencies in brothers than fathers may merely reflect the strong temporal changes in US incidence rates. Objectives: (a) to evaluate the fit of X-linked, recessive, and dominant modes of inheritance to prostate cancer incidence, specific for calendar year, age, and race, in population-based samples of US and Canadian families; and (b) to evaluate a simple multifactorial model for familial aggregation of prostate cancer due to shared low-penetrance variants of many genes or shared lifestyle factors. Methods: The data consist of reported prostate cancer incidence in first-degree relatives of 1719 white, African-American, and Asian-American men with and without prostate cancer at ages < 70 years. Model parameters were estimated by maximizing a pseudo-likelihood function of the data, and goodness of model fit was assessed by evaluating discrepancies between observed and expected numbers of pairs of relatives with prostate cancer. Results: After adjusting for temporal trends in prostate cancer incidence rates we found that the X-linked model fit poorly, underpredicting the observed number of affected father–son pairs. This also was true of the recessive model, although the evidence for poor fit did not achieve statistical significance. In contrast, the dominant model provided adequate fit to the data. In this model the race-specific penetrance estimates for carriers of deleterious genotypes were similar among African-Americans and whites, but lower among Asian-Americans: risk by age 80 years for carriers born in 1900 was estimated as 75.3% for African-Americans and whites, and 44.4% for Asian-Americans. None of the Mendelian models fit the data better than did the simple multifactorial model. Conclusions: The good fit of the multifactorial model suggests that multiple genes, each having low penetrance, may be responsible for most inherited prostate cancer susceptibility, and that the contribution of rare highly penetrant mutations is small.
Similar content being viewed by others
References
Greenlee RT, Hill-Harmon MB, Murray T, Thun M(2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15-36.
Woolf CM (1960) An investigation of the familial aspects of cancer of the prostate. Cancer 13: 739-744.
Cannon LA, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR (1982) Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1: 47-69.
Meikle AW, Stanish WM (1982) Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 54: 1104-1108.
Carter BS, Carter HB, Isaacs JT (1990) Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16: 187-197.
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17: 337-347.
Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR (1991) Familial patterns of prostate cancer: a case-control analysis. J Urol 146: 1305-1307.
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86: 1600-1608.
Whittemore AS, Wu AH, Kolonel LN, et al. (1995) Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141: 732-740.
Monroe KR, Yu MC, Kolonel LN, et al. (1995) Evidence of an Xlinked or recessive genetic component to prostate cancer risk. Nat Med 1: 827-829.
Whittemore AS (1994) Prostate cancer. Cancer Surv 20: 309-322.
Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552.
Hankey BF, Feuer EJ, Clegg LX, et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024.
Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67: 1367-1375.
Ingles SA, Ross RK, Yu MC, et al. (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170.
Stanford JL, Just JJ, Gibbs M, et al. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194-1198.
Edwards SM, Badzioch MD, Minter R, et al. (1999) Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 84: 458-465.
Nam RK, Elhaji Y, Krahn MD, et al. (2000) Significance of the cag repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 164: 567-572.
Xu J, Meyers D, Freije D, et al. (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Gen 20: 175-179.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89: 3367-3371.
Gronberg H, Damber L, Damber JE, Iselius L (1997) Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 146: 552-557.
Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN (1998) Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62: 1425-1438.
Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG (2001) Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 68: 1207-1218.
Smith JR, Freije D, Carpten JD, et al. (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genomewide search. Science 274: 1371-1374.
Cooney KA, McCarthy JD, Lange E, et al. (1997) Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89: 955-959.
Berthon P, Valeri A, Cohen-Akenine A, et al. (1998) Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62: 1416-1424.
Gibbs M, Chakrabarti L, Stanford JL, et al. (1999) Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet 64: 1087-1095.
Gibbs M, Stanford JL, McIndoe RA, et al. (1999) Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64: 776-787.
Tavtigian SV, Simard J, Teng DH, et al. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27: 172-180.
Berry R, Schroeder JJ, French AJ, et al. (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67: 82-91.
McIndoe RA, Stanford JL, Gibbs M, et al. (1997) Linkage analysis of 49 high-risk families does notsupporta common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 61: 347-353. Segregation analysis of prostate cancer 481
Eeles RA, Durocher F, Edwards S, et al. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 62: 653-658.
Whittemore AS, Lin IG, Oakley-Girvan I, et al. (1999) No evidence of linkage for chromosome 1q42.2-43 in prostate cancer. Am J Hum Genet 65: 254-256.
Berry R, Schaid DJ, Smith JR, et al. (2000) Linkage analyses att he chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 66: 539-546.
Vesprini D, Nam RK, Trachtenberg J, et al. (2001) HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 68: 912-917.
Xu J, Zheng SL, Carpten JD, et al. (2001) Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 68: 901-911.
Whittemore AS, Kolonel LN, Wu AH, et al. (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652-661.
Whittemore AS, Halpern J (1997) Multi-stage sampling in genetic epidemiology. Stat Med 16: 153-167.
Siegmund KD, Whittemore AS, Thomas DC (1999) Multistage sampling for disease family registries. J Natl Cancer Inst Monogr 26: 43-48.
Little JA, Rubin DB (1987) Statistical Analysis with Missing Data. New York: John Wiley & Sons.
Whittemore AS (1997) Multistage sampling designs and estimating equations. J R Stat Soc, Series B 59: 589-602.
Breslow N (1990) Tests of hypotheses in overdispersed Poisson regression and other quasi-likelihood models. J Am Stat Assoc 85: 565-571.
Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504.
Whittemore AS, Halpern J, Gong G (1998) Testing covariance structure in multivariate models: application to family disease data. J Am Stat Assoc 93: 518-525.
Gong G, Whittemore AS (1999) Estimating genetic influence on disease from population-based case-control data: application to cancers of the breast and ovary. Stat Med 18: 3321-3336.
Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO (1996) Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 88: 1216-1221.
Doll R, Payne P, Waterhouse J (1966) Cancer Incidence in Five Continents. IARC Scientific Publications, Vol. I. Lyon: International Agency for Research on Cancer.
Waterhouse J, Muir C, Correa P, Powell J (1976) Cancer Incidence in Five Continents. IARC Scientific Publications No. 15. Vol. III Lyon: International Agency for Research on Cancer.
Waterhouse J, Muir C, Shanmugaratnam K, Powell J (1982) Cancer Incidence in Five Continents. IARC Scientific Publications No. 42. Vol. IV. Lyon: International Agency for Research on Cancer.
Muir C, Waterhouse J, Mack T, Powell J, Whelan S (1987) Cancer Incidence in Five Continents. IARC Scientific Publications No. 88. Vol. V. Lyon: International Agency for Research on Cancer.
Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (1992) Cancer Incidence in Five Continents. IARC Scientific Publications No. 120. Vol. VI. Lyon: International Agency for Research on Cancer.
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in Five Continents. IARC Scientific Publications No. 143. Vol. VII. Lyon: International Agency for Research on Cancer.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gong, G., Oakley-Girvan, I., Wu, A.H. et al. Segregation analysis of prostate cancer in 1719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control 13, 471–482 (2002). https://doi.org/10.1023/A:1015755219674
Issue Date:
DOI: https://doi.org/10.1023/A:1015755219674